Correction to: Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer (Nature Medicine, (2018), 24, 5, (638-646), 10.1038/s41591-018-0007-9)
Jacqulyne P. Robichaux, Yasir Y. Elamin, Zhi Tan, Brett W. Carter, Shuxing Zhang, Shengwu Liu, Shuai Li, Ting Chen, Alissa Poteete, Adriana Estrada-Bernal, Anh T. Le, Anna Truini, Monique B. Nilsson, Huiying Sun, Emily Roarty, Sarah B. Goldberg, Julie R. Brahmer, Mehmet Altan, Charles Lu, Vassiliki PapadimitrakopoulouKaterina Politi, Robert C. Doebele, Kwok Kin Wong, John V. Heymach
Research output: Contribution to journal › Comment/debate › peer-review
Fingerprint
Dive into the research topics of 'Correction to: Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer (Nature Medicine, (2018), 24, 5, (638-646), 10.1038/s41591-018-0007-9)'. Together they form a unique fingerprint.